CN1214017C - 四唑衍生物 - Google Patents

四唑衍生物 Download PDF

Info

Publication number
CN1214017C
CN1214017C CNB018126987A CN01812698A CN1214017C CN 1214017 C CN1214017 C CN 1214017C CN B018126987 A CNB018126987 A CN B018126987A CN 01812698 A CN01812698 A CN 01812698A CN 1214017 C CN1214017 C CN 1214017C
Authority
CN
China
Prior art keywords
tetrazolium
compound
formula
xanthene
formic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018126987A
Other languages
English (en)
Chinese (zh)
Other versions
CN1441791A (zh
Inventor
S·约利多
V·穆泰尔
E·维埃拉
J·维希曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1441791A publication Critical patent/CN1441791A/zh
Application granted granted Critical
Publication of CN1214017C publication Critical patent/CN1214017C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB018126987A 2000-07-13 2001-07-05 四唑衍生物 Expired - Fee Related CN1214017C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115170.3 2000-07-13
EP00115170 2000-07-13

Publications (2)

Publication Number Publication Date
CN1441791A CN1441791A (zh) 2003-09-10
CN1214017C true CN1214017C (zh) 2005-08-10

Family

ID=8169240

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018126987A Expired - Fee Related CN1214017C (zh) 2000-07-13 2001-07-05 四唑衍生物

Country Status (19)

Country Link
US (1) US6399641B1 (enExample)
EP (1) EP1303499B1 (enExample)
JP (1) JP3971298B2 (enExample)
KR (1) KR100504292B1 (enExample)
CN (1) CN1214017C (enExample)
AR (1) AR029706A1 (enExample)
AT (1) ATE332895T1 (enExample)
AU (2) AU2001278472B2 (enExample)
BR (1) BR0112465A (enExample)
CA (1) CA2415673A1 (enExample)
DE (1) DE60121447T2 (enExample)
DK (1) DK1303499T3 (enExample)
ES (1) ES2267797T3 (enExample)
MX (1) MXPA03000221A (enExample)
PA (1) PA8521901A1 (enExample)
PE (1) PE20020409A1 (enExample)
PT (1) PT1303499E (enExample)
WO (1) WO2002006254A1 (enExample)
ZA (1) ZA200210157B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512227A (ja) 2003-08-06 2007-05-17 セノミックス、インコーポレイテッド Ｔ１ｒヘテロオリゴマー味覚受容体、この受容体を発現する細胞株、および味覚化合物
EP1726585A4 (en) * 2004-03-05 2009-07-15 Banyu Pharma Co Ltd DIARYLSUBSTITUTED FIVE-GLOSS HETEROCYCLUS DERIVAT
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP3235811B1 (en) 2006-04-21 2018-07-25 Senomyx, Inc. Process of preparing oxalamides
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2093234A1 (en) 2008-02-08 2009-08-26 Nutrinova Nutrition Specialties & Food Ingredients GmbH Oligopeptides for use as taste modulators
TWI429404B (zh) 2008-03-03 2014-03-11 Senomyx Inc 異山梨醇衍生物及彼等作為風味改良劑、促味劑及促味增強劑之用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1343827A (en) * 1971-06-15 1974-01-16 Science Union & Cie Acylaminotetrazoles and process for preparing them
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
GB9626151D0 (en) * 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds
NZ524395A (en) * 1997-12-10 2004-10-29 Nps Pharma Inc Anticonvulsant and central nervous system-active bis(fluorophenyl) alkylamides
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives

Also Published As

Publication number Publication date
EP1303499B1 (en) 2006-07-12
EP1303499A1 (en) 2003-04-23
AR029706A1 (es) 2003-07-10
KR100504292B1 (ko) 2005-07-28
CN1441791A (zh) 2003-09-10
AU2001278472B2 (en) 2006-08-03
DE60121447D1 (de) 2006-08-24
DE60121447T2 (de) 2007-02-01
BR0112465A (pt) 2003-07-22
JP2004504308A (ja) 2004-02-12
PT1303499E (pt) 2006-11-30
CA2415673A1 (en) 2002-01-24
AU7847201A (en) 2002-01-30
US20020022648A1 (en) 2002-02-21
ATE332895T1 (de) 2006-08-15
PA8521901A1 (es) 2002-04-25
MXPA03000221A (es) 2003-06-06
ES2267797T3 (es) 2007-03-16
PE20020409A1 (es) 2002-05-21
KR20030016390A (ko) 2003-02-26
ZA200210157B (en) 2004-03-15
WO2002006254A1 (en) 2002-01-24
JP3971298B2 (ja) 2007-09-05
US6399641B1 (en) 2002-06-04
DK1303499T3 (da) 2006-10-30

Similar Documents

Publication Publication Date Title
CN1441791A (zh) 四唑衍生物
CN1092643C (zh) 用于增强记忆的氨甲基苯基咪唑衍生物
CN1556703A (zh) 具有cb1激动活性,cb1部分激动活性或cb1拮抗活性的1h－咪唑衍生物
CN1247571C (zh) 新颖的2h－哒嗪－3－酮衍生物、含有它们的药物组合物和活性成分的制备方法
CN1262678A (zh) 三唑化合物及其作为多巴胺－d3－配体的应用
CN1050187A (zh) 新的喹啉化合物及其制备方法
CN1261885A (zh) 2－取代的4,5－二芳基咪唑
CN1429215A (zh) 三唑衍生物
CN1665785A (zh) 2－氰基－4－氟吡咯烷衍生物或其盐
CN1265033A (zh) 二芳基咪唑衍生物:新的一类npy特异性配体
CN1589269A (zh) 杂1,2－二氢化茚:一类新型有效的大麻配体
CN1274288A (zh) 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1337395A (zh) 新的二苯脲化合物、其制备方法和含有该化合物的药物组合物
CN1791576A (zh) 代谢型谷氨酸受体的苯甲酰胺调节剂
CN1209358C (zh) αLβ2介导细胞粘连的抑制剂
CN1832945A (zh) 二苯基吡啶衍生物,其制备及治疗用途
CN1134695A (zh) 具有血小板凝聚抑制作用的新颖化合物
CN1265660A (zh) 2－(4－芳基或杂芳基－哌嗪－1－基甲基)－1h－吲哚衍生物
CN1264378A (zh) 作为nk－2和nk－3受体拮抗剂的喹啉－4－甲酰胺衍生物
CN1323306A (zh) 萘啶衍生物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
CN1184964C (zh) 羰基氨基衍生物对抗cns障碍的应用
CN1487831A (zh) 用作mGluR1拮抗剂的四氢-(苯并或噻吩并)-氮杂�-吡嗪和三嗪衍生物
CN1852906A (zh) 新化合物
CN1134149A (zh) 苯基吲哚化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050810

Termination date: 20090805